IDH2 and astrocytoma (excluding glioblastoma): When this same methylome analysis was subsequently applied to a cohort of 245 IDH-mutant astrocytomas from The Cancer Genome Atlas (TCGA), two separate clusters were identified: one comprising 57 cases with significantly higher levels of CNV (21.2% vs. 7.4%), other evidence of CIN in the initial biopsy/resection, and worse PFS (median survival of 38 vs. 62 months) and OS (51 vs. 98 months) compared to a cluster of 188 cases that had lower CNV and better clinical outcomes.